Home / Growth Plan – Subscription Terms & Conditions /

Growth Plan – Subscription Terms & Conditions

Growth Plan – Subscription Terms & Conditions

By subscribing to the Growth Plan, you agree to the following plan-specific terms. These apply in addition to the MAI CDMO Legal Terms.

1. What’s included

With the Growth Plan you get:

  • A dedicated, branded CDMO profile visible to all visitors.
  • Leads submitted via your profile form are sent to you promptly after our anti-spam review.
  • Leads generated through other promotional activities (such as fairs and events) are also communicated to you with priority.
  • Priority support from an assigned Account Manager.
  • Performance reports with recommendations (delivered twice per year: January–May and September–December).
  • Access to pharma projects posted on the platform by pharmaceutical companies.
  • Network access: See which companies are registered and send them targeted inquiry forms.

Note: Access to the network and projects facilitates outreach but does not guarantee any response, lead volume, or awarded projects.

2. Subscription and pricing

The Growth Plan is €49.99 per month, billed annually at a total of €599.88. VAT not included.

3. Renewal

Available payment methods:

  • SEPA direct debit
  • ACH
  • Card Payment

The subscription automatically renews at the end of each term unless cancelled by the subscriber at least thirty (30) days in advance.

Fees may be updated upon prior notice. If the subscriber does not accept the revised fee, it may cancel the subscription before the effective date.

The subscriber shall be responsible for keeping its contact details up to date.

4. Expiry and downgrade

In the event of non-payment, a grace period of forty-eight (48) hours shall be granted. If payment is not received in the provider’s account within this period, the subscription will automatically switch to the Basic Plan, with reduced features. This clause is established pursuant to the freedom of contract recognized in the Spanish Commercial Code (arts. 1 et seq.) and Civil Code (art. 1,261), as well as Law 7/1998, of April 13, on General Conditions of Contracting, last updated 16/03/2019, ensuring clarity, precision, and transparency for the parties.

Industry News

Check out the latest trends in the contract manufacturing industry

MAI CDMO Network Collaborates with IMAPAC for Biologics CDMO Europe 2025
MAI CDMO Network Collaborates with IMAPAC for Biologics CDMO Europe 2025

2025-09-22

Connecting Leaders in Biologics Manufacturing

See more
MAI CDMO Launches Website in 5 Languages to Support Global Clients
MAI CDMO Launches Website in 5 Languages to Support Global Clients

2025-06-20

MAI CDMO is now available in 5 languages for a seamless multilingual experience.

See more
Counting down to CPHI Americas 2025!
Counting down to CPHI Americas 2025!

2025-05-18

Let’s connect at CPHI Americas

See more

View all News

WORLD CLASS CONTRACT MANUFACTURERS

Leading CMOs and CDMOs

Italy Europe
 
Aenova Group - Location Latina, Italy
Aenova Group - Location Latina, Italy

Competence Center animal health products and sterile technologies.

Activity: FDF / DRUG PRODUCTS, BIOLOGICS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: EMA (EU GMP), FDA (cGMP), ANVISA (Brazil B-GMP),...

Markets: FDA (USA), EMA (EU), ANVISA (Brazil), Russian...

United States North America
 
Cambrex Charles City
Cambrex Charles City

Our 400+ team members in Charles City specialize in late-phase and commercial API development and cGMP manufacturing.

Activity: CHEMICAL-SYNTHETIC manufacturing

Uses: Investigational, Commercial (Phase IV), Human

Services: Development services, Manufacturing services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: EMA (EU GMP), FDA (cGMP), Health Canada (Canada...

Markets: FDA (USA), EMA (EU), PMDA (Japan), Health Canada...

France Europe
 
Cenexi Hérouville Saint Clair
Cenexi Hérouville Saint Clair

The Hérouville-Saint-Clair site, located near Caen, in Normandy, specializes in the manufacture and filling of injectable and non-injectable sterile liquid products. It has a pharmaceutical surface area of 17,900 m2 over 10 hectares and employs 290 people.

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human

Services: Regulatory services, Manufacturing services,...

Batch Size / Reactor: Small, Medium

Certifications: EMA (EU GMP), FDA (cGMP), NMPA (China GMP), ANVISA...

Markets: FDA (USA), EMA (EU), PMDA (Japan), MHRA (UK), TGA...

Spain Europe
 
Grifols International | Barcelona Plant
Grifols International | Barcelona Plant

Sterile manufacturing solutions (small molecules) in flexible bags and vials.

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: ISO, EMA (EU GMP), FDA (cGMP), Health Canada...

Markets: FDA (USA), EMA (EU), PMDA (Japan), Health Canada...

United States North America
 
Lannett CDMO
Lannett CDMO

Lannetts main manufacturing site sits in Seymour, Indiana, and includes capabilities for Oral Solid Dose (OSD) and Liquids.

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: EMA (EU GMP), FDA (cGMP), Health Canada (Canada...

Markets: COFEPRIS (Mexico), FDA (USA), EMA (EU), PMDA...

Switzerland Europe
 
Ophtapharm, a Sentiss Company
Ophtapharm, a Sentiss Company

Ophtalmic and Otic - Solutions, suspensions, emulsions, ointments and gels - FDA Approved facility

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Regulatory services, Development services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: ISO, EMA (EU GMP), FDA (cGMP), World Health...

Markets: FDA (USA), EMA (EU)

United States North America
 
Pharmaron API Commercial Synthesis Coventry (US)
Pharmaron API Commercial Synthesis Coventry (US)

Commercial API Small Molecules Synthesis

Activity: CHEMICAL-SYNTHETIC manufacturing

Uses: Investigational, Commercial (Phase IV), Human,...

Services: Development services, Manufacturing services

Batch Size / Reactor: Small, Medium, Large

Certifications: ISO, FDA (cGMP), ECOVADIS

Markets: FDA (USA), EMA (EU), PMDA (Japan), Health Canada...

Spain Europe
 
VIVUNT PHARMA
VIVUNT PHARMA

CDMO Sterile Oncology Drugs

Activity: FDF / DRUG PRODUCTS manufacturing

Uses: Investigational, Commercial (Phase IV), Human

Services: Manufacturing services, Analytical / QC services,...

Batch Size / Reactor: Small, Medium, Large

Certifications: EMA (EU GMP)

Markets: EMA (EU)

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

Mabion
Sylentis
Ascil
Cambrex
ADRAGOS PHARMA
VIVUNT